A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

In Vitro Generation of Heart Field-specific Cardiac Progenitor Cells

5.9K views

⸱

DOI:

10.3791/59826

⸱

July 3rd, 2019

 ,  , 

In This Article

Summary

The purpose of this method is to generate heart field-specific cardiac progenitor cells in vitro in order to study the progenitor cell specification and functional properties, and to generate chamber specific cardiac cells for heart disease modelling.

Abstract

Pluripotent stem cells offer great potential for understanding heart development and disease and for regenerative medicine. While recent advances in developmental cardiology have led to generating cardiac cells from pluripotent stem cells, it is unclear if the two cardiac fields - the first and second heart fields (FHF and SHF) — are induced in pluripotent stem cells systems. To address this, we generated a protocol for in vitro specification and isolation of heart field-specific cardiac progenitor cells. We used embryonic stem cells lines carrying Hcn4-GFP and Tbx1-Cre; Rosa-RFP reporters of the FHF and the SHF, respectively, and live cell immunostaining of the cell membrane protein Cxcr4, a SHF marker. With this approach, we generated progenitor cells which recapitulate the functional properties and transcriptome of their in vivo counterparts. Our protocol can be utilized to study early specification and segregation of the two heart fields and to generate chamber-specific cardiac cells for heart disease modelling. Since this is an in vitro organoid system, it may not provide precise anatomical information. However, this system overcomes the poor accessibility of gastrulation-stage embryos and can be upscaled for high-throughput screens.

Introduction

The use of pluripotent stem cells (PSCs) has revolutionized the field of cardiac regeneration and personalized medicine with patient-specific myocytes for disease modeling and drug therapies1,2,3,4. More recently, in vitro protocols for the generation of atrial vs ventricular as well as pacemaker-like PSC-derived cardiomyocytes have been developed5,6. However, whether cardiogenesis can be recreated in vitro to study cardiac development and subsequently generate ventricular chamber-sp....

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: In vitro generation of heart field-specific mouse cardiac progenitor cells (Figure 1).

1. Maintenance of Mouse ESCs

  1. Grow mESCs (mESCsTbx1-Cre; Rosa-RFP; HCN4-GFP, mESCIsl1-RFP)25 on 0.1% (w/v) gelatin coated T25 flasks in 2i medium (870 mL of glascow minimum essential medium (GMEM), 100 mL of fetal bovine serum (FBS), 10 mL of GlutaMAX, 10 mL of non-essential amino acids, 10 mL of sodium pyruvate, 3 μL of beta-mercaptoethanol, 20 μL of Lif (200 U/mL), 0.3 μM CHIR99021 and 0.1 μM PD0325901).

Access restricted. Please log in or start a trial to view this content.

Results

After approximately 132 h of differentiation, Tbx1-RFP and Hcn4-GFP CPCs can be detected using a fluorescent microscope (Figure 2). Generally, GFP and RFP cells appear approximately around the same time. The two populations of CPCs continue to expand in close proximity and commonly in a complementary pattern. Adjusting the concentrations of Activin A and BMP4 will alter the percentages of FHF vs SHF CPCs (Figure 3). CPC specification in vitro was primarily deter.......

Access restricted. Please log in or start a trial to view this content.

Discussion

In our protocol, we describe a methodology to generate cardiac spheroids and isolated heart field-specific CPCs. Those can be used to study mechanisms of CPC specification and their properties, as well as for cardiac chamber-specific disease modelling. One previously published work used a mESC line with two fluorescent reporters (Mef2c/Nkx2.5) to study cardiogenesis in vitro, however, both those markers are expressed at embryonic day 9.5-10 when cardiomyocytes are already formed26. To our knowledg.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing for disclosures.

Acknowledgements

E. T. was supported by The Magic That Matters and AHA. C. K. was supported by grants from NICHD/NIH (R01HD086026), AHA, and MSCRF. 

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
β-mercaptoethanolSigmaM6250
0.1% (w/v) GelatinEMD MilliporeES-006-B
100 mM Sodium PyruvateGibco11360
100x Pen/StrepGibco15070-063
1x PBS w/o Calcium and MagnesiumThermo Fisher Scientific21-040-CV
20% ParaformaldehydeThermo Fisher Scientific50-980-493
5 mL Polystyrene round-bottom tube with a 40μm cell strainerBD Falcon35223
Activin AR & D Systems338-AC-010
Ascorbic AcidSigmaA-4544
B27 minus vitamin A (50x)Thermo Fisher Scientific12587010
BMP4R & D Systems314-BP
Bovine Serum AlbuminSigmaA2153
Cell sorterSonySH800Sony or any other fluorescence-activated cell sorter
Cell strainer 70μmThermo Fisher Scientific08-771-2
Centrifuge Sorvall Legend XTThermo Fisher Scientific75004508
CHIR99021Selleck chemicalsS2924
CO2 IncubatorThermo Fisher Scientific51030285
Corning Ultra Low Attachment T75 flaskCorning07-200-875
Countless II FL automated cell counterThermo Fisher Scientific
Donkey anti-mouse IgG secondary antibody, Alexa Fluor 647 conjugateThermo Fisher ScientificA-31571, Lot #1757130
Dulbecco's Modified Eagle's Medium high glucose (DMEM)Gibco11965-092
EDTASigmaE6758
ESGRO (LIF)MilliporeESG1106
EVOS FL microscopeThermo Fisher ScientificAMF4300
Fetal Bovine SerumInvitrogenSH30071.03
Glasgow’s MEM (GMEM)Gibco11710035
GlutaMAX (100x)Gibco35050-061
Ham’s F12Gibco10-080-CV
HEPESSigmaH3375
IMDMGibco12440053
Monothioglycero (MTG)SigmaM-6145
Mouse anti-Troponin T antibodyThermo Fisher ScientificMS-295-P1
N2-SUPPLEMENTGibco17502-048
Non-essential amino acid solution (NEAAInvitrogen11140-050
PD0325901SelleckchemS1036
PerCP-efluor 710 conjugated anti-Cxcr4 antibodyThermo Fisher Scientific46-9991-82
Suspension culture dish 150 mm x 25 mmCorning430597
T25 flasksCorning353109
TrypLE (Trypsin)Gibco12604
Y-27632 (ROCK inhibitor)Stem cell technologies72304

References

  1. Laflamme, M. A., Murray, C. E. Heart regeneration. Nature. 473 (7347), 326-335 (2011).
  2. Spater, D., Hansson, E. M., Zangi, L., Chien, K. R. How to make a cardiomyocyte. Development. 141 (23), 4418-4431 (2014).
  3. Birket, M. J., Mummery, C. L.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Heart Field Progenitor CellsEmbryonic Stem CellsFluorescent Reporter AssayFlow Cytometry AnalysisCell Isolation ProtocolCardiac Spheroid FormationFACS Cell SortingCxcr4 Surface MarkerHcn4-GFP Reporter